Legal and Practical Issues in Cannabis Regulation
May 24-25, 2022
Speaker Biographies

ELISABETH BERRY is the Chief Operating Officer of PSI Labs, a multi-state cannabis testing laboratory. As COO, Elisabeth oversees the lab's finance, HR, compliance and operations teams with a focus on guiding the company' strategic planning and expansion. Prior to joining PSI Labs, Elisabeth led operations and growth initiatives across diverse industries such as venture capital, food & beverage tech and healthcare M&A operations, supporting businesses and organizations to scale strategically and sustainably. Elisabeth's passion for early stage companies has led to participation on a number of investment review committees as well as board positions across private and not-for-profit organizations, including her current board role with the Autism Alliance of Michigan. Elisabeth holds an MBA from George Washington University, a Graduate Certificate in Public Health from the University of Michigan's School of Public Health and a bachelor's degree in Economics from the University of Michigan.

NORMAN BIRENBAUM is one of the country's preeminent cannabis policy advisors and regulatory experts. Norman has served as the chief cannabis regulator and policy official for the states of New York and Rhode Island. Mr. Birenbaum was also the founding President of the Cannabis Regulators Association (CANNRA), an association whose members represent the primary cannabis regulatory agencies from across the country. CANNRA provides a forum for regulators to engage with each other and external stakeholders to identify and develop best practices and model policies. CANNRA also provides policy makers and regulatory agencies with the resources to make informed decisions when considering whether and how to legalize and regulate cannabis. In 2019 Norman was appointed as New York State's first Director of Cannabis Programs. Norman oversaw the regulation, administration, and policy development for New York State's medical marijuana and industrial hemp industries and lead the state's efforts to legalize cannabis for adult-use. This work resulted in the passage of the Marijuana Regulation and Taxation Act (MRTA) legalizing cannabis for adult-use and creating a consolidated Office of Cannabis Management to oversee all cannabis industry sectors within the state. Following passage of the MRTA, Norman oversaw the establishment of the Office of Cannabis Management and coordinated adult-use cannabis implementation across all state agencies. As Director, he also oversaw the creation and implementation of a new regulatory structure for CBD and cannabinoid hemp derived products which allowed them to be sold as a food, beverage, or dietary supplement within New York. Before joining New York State, Norman established the Rhode Island Office of Cannabis Regulation where he oversaw Rhode Island's medical marijuana and industrial hemp programs and led Governor Gina Raimondo's efforts to reform Rhode Island's medical marijuana programs and legalize cannabis for adult use. Before working in cannabis, Norman served on the staffs of US Senator Elizabeth Warren and Massachusetts Governor Deval

Patrick. Norman is now in private practice providing cannabis industry stakeholders with strategic consulting services. His practice focuses on advising public officials and government agencies on cannabis policy, regulatory development, and the implementation and oversight of new cannabis markets.

WILLIAM BOGOT is a partner at Fox Rothschild LLP where he is Co-Chair of the firm's Cannabis Law Practice. Representing some of the largest multi-state cannabis operators in the country, Bill litigates a range of civil and regulatory issues. Recent successes include securing coveted licenses in key markets and waging challenges against administrative and court license denials and disciplinary actions. Bill also helps power players in the recreational and medical cannabis space navigate complex regulations and facilitate industry-shaping mergers and acquisitions. His multidisciplinary practice reaches major cannabis markets across the country, assisting private and public cannabis companies with a range shareholder liability, venture capital, taxation, employee, trademark and financial services issues. In Illinois' cannabis market, Bill spearheaded efforts that amended the Illinois Supreme Court Rules to allow for legal representation of cannabis clients and has served regional clients since medical marijuana was legalized in 2013. Prior to joining Fox Rothschild, Bill was a partner at Nixon Peabody (previously Ungaretti & Harris). Bill was also Acting General Counsel and Legal Counsel to the Illinois Gaming Board for over seven years. Early in his legal career, he was Assistant General Counsel to the Illinois House of Representatives and the judicial law clerk for the Honorable Aaron Jaffe in the Chancery Division of the Circuit Court of Cook County.

BILL BOOKOUT is a founding member of the National Animal Supplement Council, serving as President from 2002 to May 2012, returning as President in February 2014 and continuing as chairman of the Board of Directors of the nonprofit organization. Mr. Bookout was President of Genesis Limited, a company he founded in 1999 that provides both feed and health products for companion animals. In March of 2012, Genesis was acquired by Kemin Industries Inc., a privately held, family-owned company that has nearly 1500 employees and operates in more than 90 countries. Mr. Bookout has been selected by Health Canada to serve on the Expert Advisory Committee for Veterinary Natural Health Products. Prior to founding Genesis, he spent 15 years in the human medical device and animal health industries, including executive positions with Medex Medical, the All-Care Animal Referral Center (a specialty referral veterinary hospital) and AnaMed International, and was Director of Sales & Marketing for Marquest Medical Products. Mr. Bookout received his bachelor's degree in physical sciences from the University of Wyoming and an MBA from Pepperdine University, Presidents and Key Executive Program. Bill also is very much committed to "giving something back" both personally and professionally. Each year at the annual meeting NASC selects an organization and helps with a fundraising effort. Organizations that NASC has helped include, Best Friends Animal Sanctuary, Big Cat Rescue, Reins Therapeutic Horsemanship Program and the Warrior Dog Foundation.

THEODORE L. CAPUTI is a public health research consultant specializing in behavioral public health and regulatory science. His recent research includes analyses of the marketing practices of recreational and medical marijuana companies. He coined the term “Research as Marketing” to describe how medical marijuana companies sponsor and publicize methodologically weak research to convey unfounded health claims while skirting existing health marketing regulations. He has authored over 30 publications in peer-reviewed journals such as the Journal of the American Medical Association and the American Journal of Public Health, and his work has been featured in news outlets such as the New York Times, the LA Times, and CNN. He earned his undergraduate degree from the University of Pennsylvania, his Master of Public Health from University College Cork, and his master’s in health sciences from the University of York, and he is the recipient of the Mitchell and Marshall Scholarships.

SARAH A. CHASE has dedicated her professional career to working behind the scenes to champion both public and private projects that are mission-driven and have a clear focus on improving communication to advance social justice. She is honored to serve as the first Executive Director for the Council for Federal Cannabis Regulation (CFCR). For more than 15 years, Sarah has worked primarily with start-up companies in the media, broadcast, and communication space. She has held various COO, CFO, Communication, and Business Development positions and worked closely with executive teams in the United States, Europe, and Asia to translate high-level visions into realized corporate entities. From 2016 to 2020, Sarah served as the Chief Operating Officer for the Alda Communication Training Company (ACT), helping her mentor (legendary actor, writer, and director), Alan Alda, bring his proven improv and communication methods to the world. Working closely with Alan, Sarah established the first-of-its-kind public-private partnership (PPP) with the State University of New York (SUNY). The company grew from $0 to more than $2.5M in net profit within the first 2-years. Because of this growth and success, Alan was able to realize his dream of donating the profits directly back to the Alan Alda Center for Communicating Science at Stony Brook University. This created a win-win scenario for the Alda Center, Stony Brook / SUNY, and Alan. Sarah also served as the Executive Producer, writer, and voice-over artist for Alan's podcast, Clear+Vivid, which has had over 15-million downloads. She produced over 100 episodes with notable guests including Tom Hanks, Paul McCartney, Julie Andrews, Madeline Albright, Tina Fey, Michael J. Fox, Judge Judy, Isabella Rossellini, and many more. Sarah has led communication and media training workshops for corporate clients, as well as at the United Nations, NASA, the Nature Conservancy, and various "Shark Tank" events. She has served as an executive committee member of the National Small Business Association in Washington, DC and as a featured panelist and consultant with the Global Coalition for Aging and the Council on Foreign Relations. Before moving back to the United States, she worked from international office locations in both London and Frankfurt, where she advised a diverse range of clients and companies. She enjoyed being a featured political commentator on Sky News and BBC Radio while living abroad.

TARA LIN COUCH is an Analytical/Organic PhD Chemist who also possess a BS in Mathematics. Dr. Couch has exceptional analytical abilities and more than 30 years of diverse laboratory and regulatory experience in academic, field, contract and manufacturing environments. She is a sought-after expert on issues pertaining to quality control in pharmaceutical, dietary supplement, and tobacco manufacturing. As a consultant, Dr. Couch assists with the development, improvement and implementation of quality systems that are scientifically sound, efficient, practical and compliant with FDA regulations. She also helps clients with the conduct of FDA regulatory surveillance, follow-up, and pre-approval inspections including preparation efforts, direct support, and responding to FDA related communications such as the initial Form 4003 – Inspection Records Requests, Form 483 - List of Observations, Warning Letters, Consent Decrees, Deficiency Letters, and other information requests. She also performs mock FDA inspections, gap analyses, and contractor and laboratory audits to evaluate regulatory compliance to Current Good Manufacturing Practices (cGMPs) and other applicable statutory requirements. In addition, Dr. Couch provides cGMP and laboratory trainings via seminar, webinar and on-site presentations.

KAY DOYLE is the Director of US Public Policy & Legal Counsel for Jazz Pharmaceuticals. Prior to working at Greenwich Biosciences, now part of Jazz Pharmaceuticals, Kay was one of the inaugural Cannabis Control Commissioners for the Commonwealth of Massachusetts, charged with implementing the programs for adult use and medical use of cannabis. Kay also served as the primary counsel for the Medical Use of Marijuana Program, Food Protection Program and Tobacco Control Program for the Massachusetts Department of Public Health. Kay has also taught Marijuana Policy & Law as an adjunct professor for the New England School of Law. Prior to public service, Kay practiced land use and civil rights law, litigating in state and federal trial and appellate courts, including the US Supreme Court.

MADELEINE GIAQUINTO is manager of regulatory affairs at Greenleaf Health, Inc. She provides clients with timely analysis of FDA regulations, policies, and guidance documents related to good practice standards for FDA-regulated products, including drugs, biologics, medical devices, CBD, and tobacco. In addition, she advises clients on strategic engagement with FDA regarding a range of compliance-focused issues, such as remediating deficiencies identified in FDA Form 483 observations and FDA warning letters, as well as building mature quality management systems at manufacturing facilities within FDA's purview. Madeleine has worked in diverse settings across the life science landscape, including legal, government affairs, and public health policy practices. She has a BS in biology from Georgetown University and a JD from George Mason University School of Law.

TODD HARRISON is a partner at Venable LLP where he guides clients through the myriad government regulations associated with food and drug labeling and marketing. Working extensively in the areas of food and dietary supplement safety, labeling, and advertising claims, Todd helps clients in the consumer products, drug and medical device, and dietary products industries comply with government regulations. He regularly achieves favorable results in defending clients against Federal Trade Commission (FTC) advertising complaints, enforcement actions, and prosecutions, and overcoming competitor challenges in courts and other fora. Todd has substantial experience in food and dietary supplement marketing, including health claims, structure/function claims, and nutrient content claims. He is also well versed in federal, state, and international consumer protection agency rules related to drugs, food, supplements, homeopathic remedies, medical devices, and cosmetics. He concentrates on compliance and cooperation with the Food and Drug Administration (FDA), the Department of Agriculture's Food Safety and Inspection Service (FSIS), the Animal and Plant Health Inspection Service (APHIS), the Agricultural Marketing Service (AMS), the FTC, and the Drug Enforcement Administration (DEA). Todd advises clients on labeling requirements, organic products, and genetically modified organisms — developing strategies for companies to communicate information about their products without running afoul of agency regulatory requirements. He has assisted companies with compliance issues, including Hazard Analysis and Critical Control Points (HAACP), best practices in manufacturing, product recalls versus market withdrawals, inspections, warning letters, FDA and the FSIS standards of identities compliance, importing meat and poultry products into the United States, and recordkeeping. Todd drafts opinion letters regarding the status of food ingredients in the United States and assists in the preparation of food additive petitions, Generally Recognized as Safe (GRAS) notifications, and new dietary ingredient notifications. He also helps companies develop self-determined GRAS positions for food ingredients.



JONATHAN A. HAVENS is a partner at Saul Ewing Arnstein & Lehr LLP, where he serves as co-chair of both the firm's Cannabis Law and Food, Beverage & Agribusiness Practices. Companies in the cannabis (both hemp and marijuana), life sciences, food and beverage, and cosmetics industries turn to Jonathan for advice on how to get and keep their products on the market. Since 2019, Chambers USA has recognized Jonathan as one of America's leading lawyers in cannabis law. In 2021, Law360 selected Jonathan as a cannabis law rising star, making him one of only five attorneys nationwide to receive that honor. He is regularly interviewed by mainstream and trade press outlets, alike, and has been quoted by or authored pieces for The New York Times, The Los Angeles Times, Reuters, CNBC, WIRED, MarketWatch, Engadget, Law360, High Times Magazine, and Marijuana Business Daily, among others. Jonathan began his legal career as a regulatory counsel with the US Food and Drug Administration, and prior to law school, Jonathan served as a legislative aide in both the US Senate and US House of Representatives.

JAE KIM is an associate in DLA Piper's FDA Regulatory Group, and advises clients in the life sciences, food and beverage, hemp and CBD, and consumer products industries. Jae provides regulatory compliance and risk management advice to companies with products and operations subject to regulation by FDA, USDA, TTB, DEA, and FTC, as well as state regulatory authorities. Her broad regulatory practice encompasses medical devices, drugs (prescription and OTC), dietary supplements, food and beverage, alcohol, hemp and CBD products, tobacco/ENDS, and cosmetics. As part of her regulatory practice, she regularly counsels clients on regulatory issues that arise throughout the product life cycle, including product development and approval strategy, current good manufacturing practices (cGMPs), state and federal licensing and registration, labeling, advertising and promotion, inspections, agreements pertaining to quality and regulatory issues, recall management, and regulatory enforcement actions. Jae has extensive experience in conducting regulatory due diligence on behalf of companies seeking to acquire or invest in companies with a portfolio of regulated products. She also has experience in providing strategic regulatory advice and counseling for companies facing internal investigations, litigation, and arbitrations. Jae serves on the Philadelphia office's Diversity & Inclusion Committee, and is the co-manager of Cultivate, a DLA Piper blog focused on the hemp and CBD industry. She is also actively involved in the regulatory community and serves on the Food and Drug Law Institute (FDLI)'s Cannabis Products Committee, as well as the Membership Committee of Women in Bio - Philadelphia Metro chapter.

ANDREW J. KLINE advises companies involved in all aspects of cannabis law and public policy, regulatory compliance, due diligence, civil litigation, and investigations. He brings a rare combination of public policy, cannabis, and prosecutorial experience to the firm, following decades of service in the highest levels of government and in the private and nonprofit sectors. Andrew also has a deep and celebrated background in coalition creation and management. Drawing on his nearly 15 years of experience as a federal prosecutor, and public service working as policy advisor to then-Vice President Biden and counsel to then-Senator Biden, Andrew represents clients in some of most sensitive areas of law and policy. Most recently, Andrew served as public policy director for the National Cannabis Industry Association, the leading trade organization for the state-legal cannabis industry. Andrew held several critical roles in the Obama-Biden administration including as crime and drug policy advisor to the vice president, chief of staff, and senior advisor to the intellectual property enforcement coordinator, and enforcement counsel at the Federal Communications Commission (FCC). As policy advisor to then-Vice President Biden, Andrew was responsible for strategic oversight of the Office of National Drug Control Policy, including a $15 billion interagency budget process, President Obama’s drug control strategy, and the anti-drug youth media campaign. He also led White House/Executive Branch interagency working groups on complex policy issues, including prisoner reentry and drug demand policies. Andrew also co-led the strategic development, interagency coordination, and successful implementation of the president’s intellectual

property enforcement strategy including establishing the first Office of the Intellectual Property Enforcement Coordinator. Andrew's experience as a federal prosecutor includes six years as an assistant US attorney in the District of Columbia. He also served as a federal prosecutor for six years in the Civil Rights Division's Criminal Section. Andrew has first-chaired over 40 criminal jury trials, 12 bench trials, and argued numerous criminal appeals. He also conducted hundreds of multi-agency investigations during the course of his 14-year tenure at the department.

BRIAN J. MALKIN is a partner in McDermott Will & Emery LLP's Washington, DC office and counsels pharmaceutical and biologic clients on Food and Drug Administration (FDA) regulatory matters and intellectual property (IP) law, with an emphasis on patent litigation. His practice at the intersection of FDA- regulated products and patent law makes him a valuable partner to drug manufacturers, biotechnology clients, medical device companies and cannabis companies as they develop new products and protect their innovations though life cycle management, bring their products to market and pursue transactional opportunities. Brian's regulatory experience includes all types of FDA-regulated products: drugs and biologics (including animal drugs and biologics), medical devices, cannabis, foods and dietary supplements, cosmetics and tobacco products. He is a key advisor to pharmaceutical and biologic clients in the premarket, regulatory review, and marketing, enforcement and lifecycle management phases of product development. Brian works alongside his clients on drug development strategies and patent strategies across a variety of areas, including orphan drugs. With more than 20 years of FDA and intellectual property law experience, including time spent in the Office of the Commissioner and the Center for Drug Evaluation at the FDA, and a degree in biochemistry, Brian's background is uniquely tailored to the needs of life sciences innovators. He is also active in the promoting the biotechnology community and life sciences entrepreneurs in Maryland, Virginia, the District of Columbia and beyond. Brian is active in a number of leading bar associations including the Co-Chair of the Intellectual Property Community (Section) for the DC Bar and founding and current member of the New York Bar Association's Committee on Cannabis Law (and now an Executive Committee member of the Cannabis Law Section) and current member of the Executive Committee for the Food, Drug and Cosmetics Section.

LILA McKINLEY is a Staff Attorney with the Department of Consumer Protection specializing in the areas of cannabis, drug, and pharmaceutical regulation. Ms. McKinley joined the Department in 2014. Prior to joining the Department, Ms. McKinley was in private practice. Ms. McKinley obtained her JD from the University of Connecticut School of Law and her BA from the University of Connecticut. Ms. McKinley is also a co-chair of the Cannabis Regulator's Association's (CANNRA) Special Committee on Packaging, Labeling and Advertising.

DEBORAH MIRAN, former commissioner, was a member of the Natalie M. LaPrade Maryland Medical Cannabis Commission from 2013- 2016. While serving on the commission, she was also a member of the executive committee, policy, and research subcommittees, and was chair of the education subcommittee. She was responsible for developing education programs for doctors and patients and was also an integral part of crafting the current regulations. Prior to the commission she was president and founder of Miran Consulting, Inc. There she advised both brand and generic drug makers on the FDA approval process. Ms. Miran was senior director of regulatory affairs for Alpharma, a generic drug manufacturer, where she directed the submission activities for new and abbreviated new drug applications to the FDA. She has spent over 30 years in the US pharmaceutical industry. Ms. Miran received her Bachelor of Science in chemistry from Iowa State University.

DAPHNE O'CONNOR is the co-chair of Arnold & Porter's Product Liability Litigation practice group. She focuses her practice on managing and litigating complex product liability and mass tort cases. She has served as national counsel for major pharmaceutical and tobacco companies with a focus on legal strategy, appeals, settlement and complex scientific and medical issues. She also counsels clients on litigation risks and regulatory issues, including on tobacco, hemp and cannabis, as well as the litigation and compliance impacts of potential legislation. Daphne spent seven years as Vice President and Associate General Counsel for Altria Client Services, Inc. In that role, she managed all aspects of commercial and product liability litigation, including trials and appeals in both state and federal courts throughout the country. She handled a diverse portfolio of cases including personal injury and consumer fraud, class actions and large consolidations, tax refund, patent, antitrust, contract, environmental, and regulatory cases. She received her undergraduate degree from Duke University (1989) and her JD from the University of Colorado (1994).

JAMES T. O'REILLY of the University of Cincinnati College of Medicine was quoted by the US Supreme Court in March 2000 as "The experts have written..." in an FDA decision. He has been active in FDLI since 1974 and chaired the FDLI Programs Committee. In the American Bar Association he chairs the FDA Committee and formerly was the Section Chair of the ABA Section of Administrative Law & Regulatory Practice. Prior to his public health policy role he served 24 years with Procter & Gamble, retiring as Associate General Counsel for Product Safety. He has authored 56 textbooks and 234 published articles.

SHANITA PENNY is a senior vice president at Forbes Tate Partners (FTP) and has over 18 years of experience helping world class companies and startups solve complex issues and improve business performance in multiple industries. Before joining FTP, she launched and ran a boutique cannabis business strategy and public policy consultancy and continues to positively impact the burgeoning cannabis industry and the greater community. As an internationally recognized strategy consultant and certified Project Management Professional, Shanita brings an essential skillset coupled with immense passion to the cannabis industry and has achieved exceptional results for small businesses as well as multi state operators throughout the country. Over the past 7 years, she has helped clients establish and scale compliant, successful cannabis businesses. Shanita is a co-founder of DocHouse, a craft cannabis cultivator and manufacturer in Schuylkill County, Pennsylvania that was acquired by Ayr Wellness in 2020. Ms. Penny served as vice president and president of the Minority Cannabis Business Association (MCBA) from February 2017 – October 2019. Under her leadership, the MCBA hosted its inaugural Congressional Black Caucus Lobby Day, multiple policy summits and produced a model municipal ordinance that has influenced social equity policy throughout the country. Shanita provided testimony on equitable cannabis legalization in multiple cities and states and testified before the U.S. House of Representatives' Small Business Committee for a hearing to examine the role of small businesses in the cannabis industry. Ms. Penny served as a member of the Michigan Marijuana Regulatory Authority's Racial Equity Advisory Workgroup charged with developing policy ideas and recommendations to address the disparities in ownership and participation in the marijuana industry by people of color and establishing the State of Michigan as a leader on diversity, equity and inclusion in the regulated cannabis industry. She currently serves on the Board of Directors for the Alliance for Sensible Markets and on the Advisory Board of Regennabis. She lives to "end the stigma associated with cannabis" through her advocacy, businesses and responsible consumption. Shanita is a proud alumna of North Carolina Agricultural & Technical State University, as well as the University of Baltimore and Towson University.

ALENA RODRIGUEZ is the Managing Director at Rm3 Labs, the oldest analytical cannabis testing facility in Colorado. She has a MS in Biomedical Sciences and BS in Biology from Florida Atlantic University. Before joining the cannabis industry, Alena worked in molecular biology, analytical chemistry, and neuroscience laboratories. She joined Rm3 Labs in January 2016 and spent her first two years testing microbial samples and developing contaminant testing methods. She has also served as the lab's Quality Manager and led the lab's efforts to become ISO 17025 accredited. In her current position, she manages the lab's daily operations and works with governmental agencies and stakeholders to advance cannabis regulations. Alena is the Recording Secretary of the Laboratory Subcommittee of ASTM International's Committee D37 on Cannabis and the Process Validation Task Group Leader of the MED and CDPHE's Marijuana Science & Policy Work Group. She is also a member of AOAC International's Cannabis Analytical Science Program (CASP) Microbiology Working Group and a current member and former Chair of NCIA's Scientific Advisory Committee (SAC).

SHAWN "PEPPER" ROUSSEL is an attorney, ecoculinarean, and food activist. Pepper is Managing Attorney of Green Pepper Legal, consultant with Green Pepper Consulting, C0-founder of Dandelion & Moss, member Attorney with Green Justice New Orleans, and the Founding Director of Culinaria Center for Food Law, Policy, and Culture. She is also Chairperson of the Board for New Orleans Food Policy Advisory Committee, Secretary of the Living School Board of Directors, member of the LA Clinical and Translational Center LA Community Advisory Board, and an Advisor to Imagine Water Works. Pepper holds a BS in Computer Information Systems from Tulane University; an MS in Computer Information Technology with a concentration in eCommerce from Regis University; and a JD with certificates in both Environmental and International Laws from Loyola University New Orleans School of Law. She is barred and admitted in all Louisiana courts and Chitimacha Tribal Court. Her writings focus on food and environmental injustice, remediation of invasive species, food systems and Black farmers, and the environmental impacts on food.

NANDAKUMARA D. SARMA is Director, Dietary Supplements and Herbal Medicines at US Pharmacopeia (USP) responsible for strategy and external stakeholder engagement for new and innovative projects, working with global stakeholders and expert volunteers in the development of quality standards (monographs and general chapters) for dietary supplements and herbal medicines that are published in the USP Dietary Supplements Compendium and the Herbal Medicine Compendium. Before joining USP 2006, he was a post-doctoral fellow at National Cancer Institute, Bethesda, and Thomas Jefferson University, Philadelphia and was a Senior Scientific Officer at The Himalaya Drug Company, India. His research experience includes isolation and analysis of active components of botanicals and their biologic activity. He published more than 25 scientific articles in peer-reviewed journals. Dr. Sarma holds a Pharmacist degree and a PhD in pharmaceutical sciences (pharmacognosy) from Banaras Hindu University, India.

EMILY A. SELLERS is an associate at Shook, Hardy and Bacon LLP in Kansas City, Missouri. Emily is a member of the firm's Cannabis Law Practice. Emily also defends class actions and maintains a diverse practice in product liability and consumer fraud litigation domestically and internationally.

ROBERT J. SILVER is a 1982 graduate of Colorado State University's College of Veterinary Medicine. He received his master's degree in cardiopulmonary physiology in 1976, and his Bachelor's degree with honors in Animal Science in1974, also from CSU. Dr Silver is currently adjunct faculty at both the Chi University and at Lincoln Memorial University's College of Veterinary Medicine. Dr. Silver established one of the first integrative veterinary hospitals in the US in Boulder, Colorado in 1994 until he sold the practice in 2010 to focus his time and energy on post-graduate education and veterinary product development. Considered one of few true experts in veterinary cannabis, Dr. Silver has authored the popular book: "Medical Marijuana and Your Pet". A second book, Pet Health Guide to Cannabis and Medicinal Mushrooms is pending publication. It will provide an integrative health guide for veterinary conditions that are responsive to cannabis, as well as a guide to both internet and dispensary products for pets. Additionally, Silver has contributed 4 textbook chapters in two Springer publications on veterinary cannabis therapeutics in the past few years. Dr. Silver has written a peer-reviewed article in www.Animals.com titled: "The Endocannabinoid System of Animals". Dr. Silver has been providing post-graduate, continuing education classes to veterinarians, both domestically and internationally, for the past 25 years. He speaks frequently and widely at veterinary conferences and webinars as well as to the pet-owning public. His area of expertise is the integration of alternative and novel therapies with conventional veterinary therapeutics, especially as concerns medical cannabis and the medical use of herbs and nutraceuticals. Dr. Silver is president of the American College of Veterinary Botanical Medicine and Past-President of the Veterinary Botanical Medical Association. He has served on the Board of Directors of the American Holistic Veterinary Medical Association and with the Hemp Feed Coalition. Dr. Silver is a founding member of the Veterinary Cannabis Society and a member of the Cannabis Clinicians Society. Dr. Silver is currently Chief Veterinary Officer for Real Mushrooms, a Canadian medicinal mushroom company. Dr. Silver served as Chief Medical Officer of RxVitamins for the past 25 years until the company was sold in 2021. Dr. Silver served as Chief Veterinary Officer for one of the largest vertically-integrated hemp companies in the United States from 2014-2020.

CEDRIC SINCLAIR is Director of Communications and comes to the Cannabis Control Commission after serving as the Director or Communications, Marketing, and Strategic Alliances at the University of Massachusetts Boston, College of Advancing and Professional Studies. At the University, he led brand-building and lead-generation efforts for nontraditional programs that generated $35 million in annual revenue. Sinclair brings nearly 20 years of integrated marketing communications experience in the higher education and government sectors. He also taught marketing and branding courses as an adjunct faculty at Emerson College. Sinclair graduated from Emerson College with a Master of Arts in Integrated Marketing Communications and the University of Massachusetts Lowell with a Bachelor of Science in Business Administration.

SUZANNE SISLEY is an Arizona-based Internal Medicine/Psychiatry physician. Sue is also known for her pioneering policy reforms/efforts to end barriers to plant/fungi research. She served as volunteer medical director for over 40 state Cannabis Industry operating licenses from Hawaii to New Jersey since 2009. Sue has been fighting for quality REAL-WORLD cannabis/mushroom samples to conduct FDA clinical trials. She is President of Scottsdale Research Institute & best known for FDA controlled trials with Vets & 1st responders examining safety/efficacy of inhaled marijuana flower for treating severe PAIN & PTSD. Sue has been conducting studies/publishing outcomes on Cannabis for opioid reduction/substitution with her team at University of Michigan. Dr. Sisley has levied 3 FEDERAL lawsuits against the DOJ/DEA over past few years to remove barriers blocking Cannabis/Botanical research. Each petition was successful in chipping away at this 52-year-old government-enforced NIDA monopoly. The culmination of these Federal court cases resulted in Dr. Sisley finally being awarded her own DEA Schedule 1 bulk Manufacturer License which allows growing her own Cannabis Flower for any FDA-approved clinical trials. The acquisition of this Federal Cannabis cultivation license represents a dream that she shared with her mother Hanna Sisley MD who was a renowned primary care physician — they were in practice together for 20 years serving as the only mother-daughter physician team in all of Arizona. Only months later Dr. Sisley was granted the 1st DEA Schedule 1 Manufacturing License for NATURAL psilocybin mushrooms (not synthetic production). Dr. Sisley serves as President/Founder of Field to Healed Foundation, a 501c3 arm of SRI dedicated to studying botanical medicines for veterans & police/fire/EMTs to evaluate safety/efficacy of cannabis & psilocybin mushrooms for treating PTSD, pain, and potential for opioid reduction/substitution. SRI is cultivating both whole cannabis and whole psilocybin mushrooms — striving to meet GMP criteria for use in future clinical trials.… preparing drug master files to submit to FDA for both. SRI experimenting with converting harvests into extracted oil or tincture or distillate etc. Sue was highlighted in Rolling Stone Magazine last year as Top 25 Most Influential in Tech & Research along with Elon Musk.

ELIZABETH BUTTERWORTH STUTTS is Principal of Elizabeth Butterworth Stutts, Esq, PLLC. She advises clients in human and veterinary medicine and other life sciences on issues relating to clinical research, product development & promotion, professional practice & licensure, regulatory compliance, risk management, commercial contracts, telehealth and reimbursement. E.B. is a member of The Veterinary Products Committee of the Food & Drug Law Institute (FDLI), is a member of the American Veterinary Medical Law Association (AVMLA) and a member of the Veterinary Virtual Care Association (VVCA). She also serves on the Legal Advisory Board of the Center for Telehealth and e-Law (CTeL) and is a member of the Health Law Section of the Virginia Bar Association (VBA). She frequently participates in public meetings and seminars hosted by the FDA, CVM, CDER & USDA. E.B. has a BS in Biology from Vanderbilt University, earned her JD, with honors, (Law Review, Moot Court, ODK) from The University of Richmond School of Law and served as a law clerk to the Hon. J. Calvitt Clarke, Jr, US Dist Ct, ED, VA. She spent the first 15 years of her law practice concentrating in medical malpractice defense, tort & product liability and commercial litigation. E.B. was formerly a partner with

both McGuireWoods, LLP and Kaufman & Canoles, PC, in Richmond, VA. She reentered law practice in 2018. E.B. has earned her AV Preeminent rating from Martindale Hubbell and has been included in VA Business Magazine's "Legal Elite".

MATHEW R. SWINBURNE is associate director of the Network for Public Health Law's Eastern Region, which is housed at the University of Maryland School of Law. At the Network, his work focuses on issues of food safety and security, injury prevention, chronic disease, environmental health, and cannabis policy. His cannabis work includes advising legislators, state and local agencies, law enforcement, and non-profits on critical issues related to medical and adult-use. In addition, Mathew developed and taught the State and Federal Cannabis Law and Policy course for the University of Maryland School of Pharmacy's MS in Medical Cannabis Science and Therapeutics program. He also produces Cannabis Quarterly, a newsletter for public health stakeholders that covers science, law, and policy in the cannabis space.

TED THOMPSON is the senior vice president of public policy for The Michael J. Fox Foundation for Parkinson's Research. Ted has more than 25 years of experience in public policy and government affairs, serving in several nonprofit leadership positions and as staff to two members of Congress. Prior to joining the Foundation, Ted served as president and CEO of the Parkinson's Action Network (PAN), a Washington, DC-based nonprofit focused on federal policy issues affecting people with Parkinson's disease. Prior to PAN, Ted was the vice president of federal government relations at the National Multiple Sclerosis (MS) Society. At the MS Society, Ted directed overall federal strategy for the national organization, as well as coordinated strategic lobbying efforts. He was also the senior vice president of public policy and mission advancement for the National MS Society, Minnesota Chapter; the president of the National Association to Prevent Sexual Abuse of Children; and the legislative counsel/director of federal relations at the Minnesota Medical Association. Ted has also independently consulted for several nonprofits, for-profit companies and political entities. Previous to his work in nonprofit policy, Ted spent nine years working for two members of Congress. He served as chief of staff and communications director to Rep. Bill Luther (D-MN) and deputy district director for Rep. Gerry Sikorski (D-MN). He also ran for the state senate in Minnesota and while unsuccessful, the experience gives him another point of view in helping to shape policy. Ted has served on several non-profit board, most recently as a board member for the American Brain Coalition, a nonprofit comprising patient organizations and the leading professional neurological, psychological and psychiatric associations from 2013 to 2019, and as an advisory board member for the Alliance for Connected Care, an organization formed to create a statutory and regulatory environment for telehealth from 2014 to 2016. Ted holds a bachelor's degree in business administration and political science from the University of St. Thomas in St. Paul, Minnesota and a law degree from the William Mitchell College of Law in St. Paul, Minnesota

BENJAMIN C. VARADI is a Senior Fellow and Visiting Research Scholar at the Vermont Law School Center for Agriculture and Food Systems, where his current research focuses on social equity regulation in the cannabis industry. Ben teaches business and agricultural law courses at VLS, and is scheduled to teach the school's first Cannabis Law class in the summer of 2022. Prior to joining VLS, Ben was an attorney in private practice, primarily representing cannabis entrepreneurs as well as leaders in other emerging industries, regulated vices, and cultural outskirts. He holds a JD, cum laude, from Tulane University Law School, and a BA in Social Technology from Burlington College, where he completed extensive coursework on urban agriculture.

JESSICA WASSERMAN is a Washington-DC based attorney in the Food and Drug Administration (FDA) practice of WassermanRowe, LLC. She handles issues of law and regulatory compliance for hemp and cannabis companies, including for food, dietary supplement, cosmetic and medical device products. She has experience with product claims, FDA Warning Letters and Recalls as well as Drug Enforcement Agency (DEA) license applications and compliance. Jessica came to cannabis work through her expertise with both USDA, where she was an official for three years, and FDA, before which she has practiced for over a decade. Her clients include fully integrated (farm, processing, retail) companies. In addition, Jessica is involved in advocacy at the federal and state levels. Jessica is a graduate of the University of Michigan Law School.